To evaluate the usefulness of CDK6, TNRC6B, and AGO1 expression in prostate tumour tissue as potential prognosis biomarkers of PCa aggressiveness, we performed a ROC curve analysis of the above-mentioned gene expressions alone and in conjunction with serum PSA levels. This evidence concerns the gene TNRC6B and prostate neoplasm.